{"protocolSection": {"identificationModule": {"nctId": "NCT00785044", "orgStudyIdInfo": {"id": "MBG313"}, "organization": {"fullName": "GE Healthcare", "class": "INDUSTRY"}, "briefTitle": "Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event", "officialTitle": "An Open-label, Multicentre, Phase 3 Study to Demonstrate the Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event During 24 Months Followup"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-05"}, "primaryCompletionDateStruct": {"date": "2010-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-11-04", "studyFirstSubmitQcDate": "2008-11-04", "studyFirstPostDateStruct": {"date": "2008-11-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-04-08", "resultsFirstSubmitQcDate": "2017-04-25", "resultsFirstPostDateStruct": {"date": "2017-04-26", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-04-25", "lastUpdatePostDateStruct": {"date": "2017-04-26", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GE Healthcare", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The study was designed to study the utility of meta-iodobenzylguanidine (123I-mIBG) imaging to identify those participants with heart failure who would experience an adverse cardiac event during 24 months of follow-up from the administration date of 123I-mIBG in previous studies MBG311 or MBG312."}, "conditionsModule": {"conditions": ["Congestive Heart Failure"], "keywords": ["Heart Failure", "MIBG", "123I-mIBG"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "OTHER", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 471, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Group", "description": "No participants received any drug administration. No intervention conducted.", "interventionNames": ["Drug: I-123 mIBG"]}], "interventions": [{"type": "DRUG", "name": "I-123 mIBG", "description": "This was an observational study. Participants were previously dosed in separate study.", "armGroupLabels": ["Group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Numerical Heart to Mediastinum (H/M) Ratio at 3 Hours 50 Minutes Post-administration on Planar 123I-mIBG Imaging by Adverse Cardiac Events (ACEs) Status", "description": "The numerical value of 123 I-mIBG uptake (H/M ratio) at 3 hours 50 minutes post administration was calculated by dividing the counts/pixel in the total myocardium region of interest (ROI) by the counts/pixel in the 7x7 pixel mediastinal ROI. Receiver operator characteristic curves (ROC) constructed on the basis of sensitivity and specificity to identify ACEs across all H/M values were used to calculate the area under the ROC curve (AUC). The AUC was used to test for statistical significance of the prognostic usefulness of the H/M ratio. In the present MBG313 study, additional efficacy data is provided for 471 participants and new data from MBG313 were combined with data collected in MBG311 and MBG312 for efficacy analysis.", "timeFrame": "From the date of administration of 123I-mIBG in studies MBG-311 or MBG-312 up to 24 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* The subject was a Heart Failure subject who signed informed consent for MBG311, MBG312, or MBG312C.\n* The subject was administered 123I-mIBG in MBG311, MBG312, or MBG312C.\n* The subject completed the late planar imaging assessments (at a minimum) required by the protocols for MBG311, MBG312, or MBG312C.\n* The subject agreed to allow the investigator access to medical records, including those relating to subject death should this occur.\n\nExclusion Criteria:\n\n* The subject withdrew or was withdrawn from MBG311, MBG312, or MBG312C.\n* The subject was considered lost-to-follow-up (6 months without contact) in MBG311, MBG312, or MBG312C.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Heart Failure Participants who participated in: MBG311 (NCT00126425) and MBG312/312C (NCT00126438).", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "John Strohmeyer", "affiliation": "GE Healthcare", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GE Healthcare", "city": "Princeton", "state": "New Jersey", "zip": "08540", "country": "United States", "geoPoint": {"lat": 40.34872, "lon": -74.65905}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of 964 heart failure (HF) participants included in efficacy population of MBG311 (NCT00126425) and MBG312 (NCT00126438), 471 participants signed informed consent and enrolled into extension MBG313 study and provided additional efficacy data. New data from MBG313 study combined with data collected in MBG311 and MBG312 studies for efficacy analysis.", "recruitmentDetails": "In the present study MBG313 (NCT00785044), participants previously administered AdreView\u2122 (123I-mIBG \\[meta-iodobenzylguanidine\\]) in studies MBG311 (NCT00126425) and MBG312 (NCT00126438) were monitored for up to 24 months from the date of administration of 123I-mIBG.", "groups": [{"id": "FG000", "title": "AdreView\u2122- Heart Failure Group", "description": "HF participants administered AdreView\u2122 (123I-mIBG \\[meta-iodobenzylguanidine\\]) in studies MBG311 (NCT00126425) and MBG312 (NCT00126438) were monitored for up to 24 months at 6-month intervals from the date of administration of 123I-mIBG to assess the occurrence of adverse cardiac events (ACEs)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Eligible to participate in MBG313", "numSubjects": "964"}]}, {"type": "Enrolled Participants", "achievements": [{"groupId": "FG000", "comment": "Out of 964 from MBG311 and MBG312 HF participants, 471 enrolled into the extension MBG313 study.", "numSubjects": "471"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Data for 471 participants (MBG313) combined with data from MBG311 and MBG312 for efficacy analysis", "numSubjects": "468"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "496"}]}], "dropWithdraws": [{"type": "Dosed at non-participating sites", "reasons": [{"groupId": "FG000", "numSubjects": "152"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "77"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "266"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "AdreView\u2122 - Heart Failure Group", "description": "HF participants administered AdreView\u2122 (123I-mIBG \\[meta-iodobenzylguanidine\\]) in studies MBG311 (NCT00126425) and MBG312 (NCT00126438) were monitored for up to 24 months at 6-month intervals from the date of administration of 123I-mIBG to assess the occurrence of ACEs."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "964"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "62.4", "spread": "11.85"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "192"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "772"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Numerical Heart to Mediastinum (H/M) Ratio at 3 Hours 50 Minutes Post-administration on Planar 123I-mIBG Imaging by Adverse Cardiac Events (ACEs) Status", "description": "The numerical value of 123 I-mIBG uptake (H/M ratio) at 3 hours 50 minutes post administration was calculated by dividing the counts/pixel in the total myocardium region of interest (ROI) by the counts/pixel in the 7x7 pixel mediastinal ROI. Receiver operator characteristic curves (ROC) constructed on the basis of sensitivity and specificity to identify ACEs across all H/M values were used to calculate the area under the ROC curve (AUC). The AUC was used to test for statistical significance of the prognostic usefulness of the H/M ratio. In the present MBG313 study, additional efficacy data is provided for 471 participants and new data from MBG313 were combined with data collected in MBG311 and MBG312 for efficacy analysis.", "populationDescription": "Efficacy population was 961 participants who received IMP and had a consensus H/M ratio on 3 hour 50 minute planar image in MBG 311 or MBG 312. Here, number of participant analyzed = number of participants with available data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "From the date of administration of 123I-mIBG in studies MBG-311 or MBG-312 up to 24 months", "groups": [{"id": "OG000", "title": "AdreView\u2122 - HF Group (With No Adverse Cardiac Events)", "description": "HF participants administered AdreView\u2122 (123I-mIBG \\[meta-iodobenzylguanidine\\]) in studies MBG311 (NCT00126425) and MBG312 (NCT00126438) with no ACEs monitored for up to 24 months at 6-month intervals from the date of administration of 123I-mIBG."}, {"id": "OG001", "title": "AdreView\u2122- HF Group (With Adverse Cardiac Events)", "description": "HF participants administered AdreView\u2122 (123I-mIBG \\[meta-iodobenzylguanidine\\]) in studies MBG311 (NCT00126425) and MBG312 (NCT00126438) with ACEs monitored for up to 24 months at 6-month intervals from the date of administration of 123I-mIBG."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "829"}, {"groupId": "OG001", "value": "132"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.451", "spread": "0.2033"}, {"groupId": "OG001", "value": "1.394", "spread": "0.1885"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis was performed on all HF participants from both groups \"AdreView\u2122 - HF Group (With No Adverse Cardiac Events)\" and \"AdreView\u2122 - HF Group (With Adverse Cardiac Events)\" based on H/M ratio.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "nonInferiorityComment": "Analysis was performed using the null hypothesis for the AUC stated as: H0: \u03b8 \u2264A versus H1: \u03b8 \\>A, where the AUC (\u03b8) value was: 'A' selected based on the diagnostic utility desired from the use of myocardial 123 I-mIBG uptake measured using H/M ratio. A smooth parametric model of the ROC curve was fitted to the data. The AUC for the resulting model was calculated and 95% confidence interval for the AUC was reported. The hypothesis was tested using the Z-statistics at 'A' at level of 0.70.", "pValue": "<0.001", "pValueComment": "At 0.05 level of significance.", "statisticalMethod": "Z-statistic", "paramType": "Mean", "paramValue": "0.581", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.532", "ciUpperLimit": "0.630"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "description": "The main objective of the study was to monitor participants previously administered AdreView\u2122 (123I-mIBG \\[meta-iodobenzylguanidine\\]) in studies MBG311 (NCT00126425) and MBG312 (NCT00126438) to identify participants at higher risk of experiencing an adverse cardiac event up to 24 months from the date of administration of 123I-mIBG, therefore, no safety evaluations performed in this study.", "eventGroups": [{"id": "EG000", "title": "AdreView\u2122 - Heart Failure Group", "description": "HF participants administered AdreView\u2122 (123I-mIBG \\[meta-iodobenzylguanidine\\]) in studies MBG311 (NCT00126425) and MBG312 (NCT00126438) were monitored for up to 24 months at 6-month intervals from the date of administration of 123I-mIBG to assess the occurrence of ACEs.", "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Designed as a continuation of original phase 3, but objectives were built around analyses of integrated data from both studies. Distinct from endpoints used in MBG311 and MBG312. No intent to analyze current study on single original study basis."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information."}, "pointOfContact": {"title": "Jose M Zubeldia, M.D.", "organization": "GE Healthcare", "email": "jose.zubeldia@ge.com", "phone": "011-44-1494-543137"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}